The report ‘Human Papillomavirus (HPV) Testing Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2025’ is a comprehensive compilation on the human papillomavirus (HPV) testing market and contains exclusive information regarding the market analysis, growth and forecasts for the period from 2017 till 2025. HPVs is a group of viruses, and each virus is given a type called HPV Type. HPV viruses are termed as papilloma viruses owing to their tendencies to cause warts or papilloma. A few HPVs are cancer causing viruses. HPVs can be grouped into low-risk genital HPV types and high-risk genital HPV types. HPVs which are non-cancerous and cause warts are termed as low-risk genital HPVs whereas cancer causing HPVs are termed as high-risk genital HPVs. There are over 150 types of HPVs, amongst which 14 types of HPVs are highly involved in cervical cancers. Human Papillomavirus (HPV) testing detects the presence of HPVs in women’s cervix. A positive HPV test indicates that the person should be monitored to identify any possibilities of developing cancers from abnormal cells. The limitation of HPV based screening for cervical cancer is that currently HPV tests are not approved for men.
This report is divided into four distinct parts. The first part consists of the introduction to the human papillomavirus (HPV) testing market. The next section consists of the regional human papillomavirus (HPV) testing market analysis and forecast. The report also contains the competitive landscape of the global human papillomavirus (HPV) testing market and gives the list of the important players operating in this lucrative market. Towards the end, the global human papillomavirus (HPV) testing market analysis 2012–2016 and forecast 2017–2025 by region, by product, by application and by end user is stated.
In the introduction section, the pertinent market numbers of the global human papillomavirus (HPV) testing market are given along with the CAGR for the forecast period 2017-2025. The introduction also contains an executive summary of this detailed report through which the report audiences can have a cursory glance at this vast market. A list of approved products for HPV testing is also highlighted in the introduction. The macroeconomic factors affecting the human papillomavirus (HPV) testing market and their weightage factor is also given in the introduction.
The next section of the report contains the regional human papillomavirus (HPV) testing market analysis and forecast as well as important market metrics such as BPS analysis, year-on-year growth rates, absolute dollar opportunity and market attractiveness analysis of the human papillomavirus (HPV) testing market. In this section, the regional drivers, restraints and trends are also indicated to help report audiences identify factors aiding the growth of this market as well as factors hampering the growth of this market across the various assessed regions. Besides the drivers and restraints, the trends that are applicable in the global human papillomavirus (HPV) testing market are also discussed region-wise in this section of the report. In addition, key regulations pertaining to the particular region which is being discussed is also presented here. Along with this, PESTLE analysis and Porter’s Five Force analysis is also detailed in this section of the report. Both the PESTLE analysis and Porter’s Five Force analysis are presented in a regional context so that all factors operating in that particular region are covered thoroughly.
The last part of the report contains the competitive landscape of the human papillomavirus (HPV) testing market. This part constitutes information on the key market players. This competition landscape gives a dashboard view of the key companies operating in the global human papillomavirus (HPV) testing market along with their important information and broad strategy adopted to stay as leaders in the global human papillomavirus (HPV) testing market. Each of the leading companies is also profiled individually and important information about the company such as company details, company description, product portfolio along with key developments concerning the company and strategic analysis is presented.
Why should you invest in this report?
If you are ready to enter the global human papillomavirus (HPV) testing market, then this report is a comprehensive guide and will give you useful insights into this vast and lucrative market. All the aspects of HPV testing are covered in this report and information is also given on the various important regions of the world where this market is likely to boom in the near future and during the forecast period of 2017-2025 to help you plan your strategies accordingly. Besides, through this report, you can gain a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, then this report will help you gauge the strategies your competitors have adopted to stay as leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
A tested and proven research methodology for accurate estimation of market performance
Overall market size has been analyzed through historical data, primary responses, and public domain data. Revenue of companies in the human papillomavirus (HPV) testing market has been benchmarked to ascertain the market size for the base year. Macroeconomic indicators such as GDP and industry growth have been considered to forecast the market size over the eight year period. The historical growth trend of end-use industries, market participants’ performance, as well as the present macro-economic outlook has been taken into consideration for estimating the overall market trend forecast. This data is then validated using the triangulation method and is extensively scrutinized using advanced tools to garner quantitative and qualitative insights into the global human papillomavirus (HPV) testing market.
The global Human Papillomavirus (HPV) testing market is estimated to be valued at nearly US$ 630 Mn in 2017. The market is expected to reach nearly US$ 1,130 Mn by the end of 2025, reflecting a CAGR of 7.6% over the forecast period (2017–2025).
Favorable reimbursement scenario for HPV testing in North America
Various healthcare and government insurance providers are offering reimbursement for the diagnosis of chronic disorders such as cervical cancer. For instance, Medicare – U.S. government-funded health insurance provider provides reimbursement to people who are of age 65 or older and some young people with disabilities. Moreover, for cervical cancer diagnosis, Medicare covers reimbursement for one Pap test every three years or a combination of Pap test & HPV testing every five years. Favorable government policies in North America are expected to drive the overall HPV testing market during the forecast period. In the United States, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening for women without health insurance is either free or with a very little cost. This effort is aimed at increasing the number of women undergoing screening for cancer.
High sensitivity of HPV testing in low resource settings is boosting the HPV testing market in Latin America
Developing countries face intense challenges in establishing cytology-based screening programs owing to lack of capacity and resources. Cytology based screening programs require well established infrastructure for processing and interpretation of samples. Cytology based screening programs require adequate healthcare infrastructure, stringent training and quality control for efficient results. Conventional cytology screening tests offer a moderate sensitivity of 44%-78% whereas HPV DNA testing screening method offers a high sensitivity of 66%-100%. The high sensitivity of the HPV test allows increasing the screening intervals and provides an opportunity to increase screening coverage in high-risk population. The failure of cytology based screening programs in low resource settings has led to alternative methods such as HPV testing.
HPV screening tests are limited to women and this acts as a growth restraint
HPV infections can infect the genital areas of men including the skin on and around the penis or anus. These infections can also be spread to the mouth and the throat. According to CDC, about 1% of sexually active men in the U.S. have genital warts at any given time. Even when HPV infections are persistent to the male population and can cause severe diseases such as genital warts, anal cancers, penile cancers, and cancers of the oropharynx, there is currently no HPV test recommend for men. The approved tests available in the market are for screening women for cervical cancers. They are not useful for the screening of HPV-related cancers or genital warts in men. The selective product availability has restricted the growth of the market to a specific gender leading to slow growth over the forecast period.
Global Human Papillomavirus (HPV) Testing Market Attractiveness Analysis by Region
North America dominated the global human papillomavirus (HPV) testing market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. North America is anticipated to be the most attractive market with an attractiveness index of 2.6 during the forecast period. Europe is expected to be the second most lucrative market, with a market attractiveness index of 1.1 during the forecast period. The Latin America human papillomavirus (HPV) testing market represents a market attractiveness index of 0.6 and is estimated to account for 8.9% of the market share growing at a CAGR of 11.8% by 2025 end. The Asia Pacific human papillomavirus (HPV) testing market is estimated to hold 6.8% revenue share by 2017 end and is projected to account for 8.6% share by 2025 end. MEA is expected to be the least attractive market for human papillomavirus (HPV) testing with an attractiveness index of 0.2 over the forecast period.
Increasing adoption of HPV testing over Pap Smear test in the North America region
A shift in the adoption rate of HPV diagnostics testing available for screening of cervical cancers has been observed over Pap Smear test since the past few years. Pap cytology based testing was considered as the primary test earlier; however, normal cytology does not always ensure a cancer-free situation. Limitations such as high variability in results, low reproducibility, less specificity and requirement for frequent testing is associated with cytology based testing. HPV DNA testing on the other hand is more significant and sensitive for detection of precancerous lesions resulting in increasing adoption of HPV testing in the North America region. In 2014, the FDA approved the first HPV test for primary cervical cancer screening in women (aged 25 years and older) after a large study confirmed the effectiveness of HPV tests. These measures will significantly increase the adoption of HPV testing in the U.S.